Second Dengue Fever Infection Can Have Fatal Effects
Second Dengue Fever Infection Can Have Fatal Effects
Researchers from the United States and Nicaragua found someone at risk of developing more severe DHF after a second infection and so on.
Indonesia is one of the countries in the world that has the highest burden of dengue fever through a virus transmitted by mosquitoes, where the most cases are found in children. This makes the case of Dengue Hemorrhagic Fever (DHF) still a worrying health problem in Indonesia. In fact, based on data from the Directorate General of Disease Prevention and Control, the Indonesian Ministry of Health (Kemenkes) stated that the distribution of dengue cases since the first week of 2018 until the end of January 2019 was highest in East Java with 2,657 cases, followed by West Java with 2,008 cases and NTT 1,169 cases.
Based on information from the World Health Organization (WHO), DHF is a major health problem for all people in the tropical and sub-tropical regions of the world, including in Indonesia. In the past 50 years, there has been a very high and unprecedented increase in the frequency of dengue cases.
Around 3.9 billion people, in 128 countries, are at risk of being infected with the dengue virus and it is estimated that nearly 390 million cases of dengue infection occur every year. This results in every year 500,000 people needing treatment due to infection with the dengue virus and 20,000 of them die. WHO also states that Latin America, Southeast Asia and the Western Pacific are the areas with the highest rates of dengue cases currently being spread.
Dengue virus is transmitted through the bite of the aedes aegypti mosquito. After going through a viral incubation period of 4-10 days, the infected mosquito can spread the virus for the rest of its life. As for patients, infections generally occur 4-5 days (maximum 12 days) after being transmitted by the Aedes aegypti mosquito. Dengue is spread throughout the tropics with a variety of risks which are affected by rainfall, temperature and large unplanned urbanization. This disease can affect anyone, both children and adults.
Dengue virus has 4 serotypes namely DEN-1, DEN-2, DEN-3 and DEN-4. As reported by Medical Xpress, a group of researchers from the United States and Nicaragua found someone at risk of developing more severe DHF after the second infection and so on. Indonesia is an endemic area with distribution throughout the country. Symptoms that will arise such as marked by sudden fever, headache, abdominal pain, fatigue, anxiety, back eyeball pain, continuous nausea and vomiting, difficulty breathing, bleeding manifestations such as nosebleeds, bleeding gums or vomiting blood and redness in the part body surface in sufferers.
Several methods for controlling or preventing transmission of dengue virus have been adapted by the Ministry of Health (Kemenkes) of the Republic of Indonesia into efforts to Eradicate Mosquito Nests (PSN) which consist of fogging up to 3M which is closing, draining, and burying. This fumigation is only carried out in certain locations that are positively indicated by DHF and to break the chain of transmission of the Aedes aegypti mosquito. However, according to the Indonesian Minister of Health, Prof. Dr. Dr. Nila Moeloek, Sp.M (K) states that fumigation is not the main strategy in preventing DHF because fogging only uses insecticides so there is a fear of resistance in it.
To improve control and prevent the spread of dengue disease transmission, WHO issued the latest position paper in September 2018 related to dengue vaccine containing recommendations for endemic DHF countries such as Indonesia to consider the introduction of dengue vaccination as part of controlling the burden of the disease. The dengue vaccine is a vaccine to prevent dengue infection or reduce the risk of a child getting severe dengue infection. Based on the results of the study, this vaccine has the best efficacy results in children aged 9-16 years. But it should be noted beforehand, WHO has also stated that dengue vaccine should only be used for people who have previously contracted dengue disease.
In August 2016, the world's first dengue vaccine was approved by BPOM. Since then, the tetravalent dengue vaccine, which provides protection against 4 types of dengue virus, has been officially circulating in Indonesia. Indonesia is the second country in Asia to give distribution permission for dengue vaccine. At present there are 20 countries in the world that have agreed to use dengue vaccines including Indonesia, Vietnam, Thailand, Brazil, Mexico, Honduras and countries in the European Union. To reduce the number of occurrences and economic burdens due to dengue infection that are so high in Indonesia, integrated prevention measures are needed, one of which is through a provider
Researchers from the United States and Nicaragua found someone at risk of developing more severe DHF after a second infection and so on.
Indonesia is one of the countries in the world that has the highest burden of dengue fever through a virus transmitted by mosquitoes, where the most cases are found in children. This makes the case of Dengue Hemorrhagic Fever (DHF) still a worrying health problem in Indonesia. In fact, based on data from the Directorate General of Disease Prevention and Control, the Indonesian Ministry of Health (Kemenkes) stated that the distribution of dengue cases since the first week of 2018 until the end of January 2019 was highest in East Java with 2,657 cases, followed by West Java with 2,008 cases and NTT 1,169 cases.
Based on information from the World Health Organization (WHO), DHF is a major health problem for all people in the tropical and sub-tropical regions of the world, including in Indonesia. In the past 50 years, there has been a very high and unprecedented increase in the frequency of dengue cases.
Around 3.9 billion people, in 128 countries, are at risk of being infected with the dengue virus and it is estimated that nearly 390 million cases of dengue infection occur every year. This results in every year 500,000 people needing treatment due to infection with the dengue virus and 20,000 of them die. WHO also states that Latin America, Southeast Asia and the Western Pacific are the areas with the highest rates of dengue cases currently being spread.
Dengue virus is transmitted through the bite of the aedes aegypti mosquito. After going through a viral incubation period of 4-10 days, the infected mosquito can spread the virus for the rest of its life. As for patients, infections generally occur 4-5 days (maximum 12 days) after being transmitted by the Aedes aegypti mosquito. Dengue is spread throughout the tropics with a variety of risks which are affected by rainfall, temperature and large unplanned urbanization. This disease can affect anyone, both children and adults.
Dengue virus has 4 serotypes namely DEN-1, DEN-2, DEN-3 and DEN-4. As reported by Medical Xpress, a group of researchers from the United States and Nicaragua found someone at risk of developing more severe DHF after the second infection and so on. Indonesia is an endemic area with distribution throughout the country. Symptoms that will arise such as marked by sudden fever, headache, abdominal pain, fatigue, anxiety, back eyeball pain, continuous nausea and vomiting, difficulty breathing, bleeding manifestations such as nosebleeds, bleeding gums or vomiting blood and redness in the part body surface in sufferers.
Several methods for controlling or preventing transmission of dengue virus have been adapted by the Ministry of Health (Kemenkes) of the Republic of Indonesia into efforts to Eradicate Mosquito Nests (PSN) which consist of fogging up to 3M which is closing, draining, and burying. This fumigation is only carried out in certain locations that are positively indicated by DHF and to break the chain of transmission of the Aedes aegypti mosquito. However, according to the Indonesian Minister of Health, Prof. Dr. Dr. Nila Moeloek, Sp.M (K) states that fumigation is not the main strategy in preventing DHF because fogging only uses insecticides so there is a fear of resistance in it.
To improve control and prevent the spread of dengue disease transmission, WHO issued the latest position paper in September 2018 related to dengue vaccine containing recommendations for endemic DHF countries such as Indonesia to consider the introduction of dengue vaccination as part of controlling the burden of the disease. The dengue vaccine is a vaccine to prevent dengue infection or reduce the risk of a child getting severe dengue infection. Based on the results of the study, this vaccine has the best efficacy results in children aged 9-16 years. But it should be noted beforehand, WHO has also stated that dengue vaccine should only be used for people who have previously contracted dengue disease.
In August 2016, the world's first dengue vaccine was approved by BPOM. Since then, the tetravalent dengue vaccine, which provides protection against 4 types of dengue virus, has been officially circulating in Indonesia. Indonesia is the second country in Asia to give distribution permission for dengue vaccine. At present there are 20 countries in the world that have agreed to use dengue vaccines including Indonesia, Vietnam, Thailand, Brazil, Mexico, Honduras and countries in the European Union. To reduce the number of occurrences and economic burdens due to dengue infection that are so high in Indonesia, integrated prevention measures are needed, one of which is through a provider
Newer Posts
Newer Posts
Older Posts
Older Posts
Comments